Skip to main content

Table 2 Efficacy parameters

From: Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

  Actual value Changes
n mean SD n mean SD p-valuem
Serum phosphorus, mg/dL        
 Baseline 40 7.0 0.7
 Week 8 39 5.5 1.3 39 − 1.5 1.6 < 0.0001
 Week 16 33 5.6 1.5 33 − 1.4 1.8 < 0.0001
Corrected serum calcium, mg/dL        
 Baseline 40 8.6 0.9
 Week 8 39 8.6 0.8 39 0.0 1.0 0.8459
 Week 16 33 8.7 0.7 33 0.2 0.9 0.3332
Calcium-phosphorus products, mg2/dL2        
 Baseline 40 59.8 8.4
 Week 8 39 46.8 9.8 39 − 13.1 13.0 < 0.0001
 Week 16 33 48.6 12.4 33 − 11.7 16.4 0.0003
Serum intact-PTHa, pg/mL        
 Baseline 25 262.3 191.5
 Week 8 19 243.6 193.9 19 − 24.0 108.5 0.3477
 Week 16 22 336.1 589.3 17 − 50.4 137.7 0.1511
FGF23b, pg/mL        
 Baseline 40 15,282.3 13,548.6
 Week 16 33 10,999.7 10,594.0 33 − 4487.8 12,122.0 0.0412
Hbc, g/dL        
 Baseline 40 11.1 1.1     
 Week 8 39 12.6 1.1 39 1.5 1.5 < 0.0001
 Week 16 33 12.7 1.2 33 1.7 1.8 < 0.0001
RBCd, × 10−4/μL        
 Baseline 40 393.6 40.2
 Week 8 39 419.1 45.7 39 25.5 36.2 < 0.0001
 Week 16 33 410.5 53.0 33 18.8 53.1 0.0500
Hte, %        
 Baseline 40 34.9 3.1
 Week 8 39 39.3 3.7 39 4.3 4.4 < 0.0001
 Week 16 33 38.8 4.0 33 4.3 5.4 < 0.0001
Cumulative dose of ESAsf, IU        
 Baselineh 40 24,050.0 18,594.1
 Week 4i 38 24,236.8 20,653.1 38 − 526.3 12,019.1 0.7887
 Week 8j 37 26,533.8 21,679.5 37 1533.8 9123.4 0.3133
 Week 12k 39 15,762.8 15,613.6 39 − 8493.6 14,897.5 0.0010
 Week 16 l 34 14,985.3 15,135.9 34 − 9544.1 20,983.4 0.0122
Cumulative dose of IV-irong, mg        
 Baselineh 40 20.0 53.6
 Week 4i 38 14.7 38.8 38 − 6.3 41.1 0.3496
 Week 8j 37 3.2 19.7 37 − 18.4 60.1 0.0709
 Week 12k 39 0.0 0.0 39 − 20.5 54.2 0.0233
 Week 16 l 34 10.6 61.7 34 − 8.2 83.4 0.5688
Daily dose of calcium carbonate, g        
 Baseline 40 1.3 1.2
 Week 4 38 1.3 1.2 38 0.0 0.4 0.5706
 Week 8 39 1.5 1.2 39 0.2 0.6 0.0577
 Week 12 40 1.4 1.2 40 0.1 0.8 0.6348
 Week 16 33 1.4 1.2 33 0.1 0.9 0.3786
Daily dose of sucroferric oxyhydroxide, mg        
 Baseline 40 1000.0 477.0
 Week 4 38 1256.6 613.7 38 243.4 549.8 0.0097
 Week 8 39 1282.1 626.1 39 269.2 591.6 0.0072
 Week 12 40 1250.0 718.3 40 250.0 662.6 0.0220
 Week 16 34 1323.5 727.0 34 294.1 672.7 0.0156
  1. Cumulative doses of ESAs and intravenous iron were regarded as 0 when they were not administered
  2. aParathyroid hormone
  3. bFibroblast growth factor 23
  4. cHemoglobin
  5. dred blood cell count
  6. eHematocrit
  7. fErythropoiesis-stimulating agents
  8. gIntravenous iron
  9. hWeeks − 4 to 0
  10. iWeeks 0–4
  11. jWeeks 4–8
  12. kWeeks 8–12
  13. lWeeks 12–16
  14. mPaired t-test (vs. baseline)